Guangzhou Boji Medical and Biotechnological Co Ltd - Asset Resilience Ratio
Guangzhou Boji Medical and Biotechnological Co Ltd (300404) has an Asset Resilience Ratio of 13.78% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Guangzhou Boji Medical and Biotechnologi (300404) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Guangzhou Boji Medical and Biotechnological Co Ltd's Asset Resilience Ratio has changed over time. See Guangzhou Boji Medical and Biotechnologi net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Guangzhou Boji Medical and Biotechnological Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Guangzhou Boji Medical and Biotechnologi.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥230.34 Million | 13.78% |
| Total Liquid Assets | CN¥230.34 Million | 13.78% |
Asset Resilience Insights
- Moderate Liquidity: Guangzhou Boji Medical and Biotechnological Co Ltd has 13.78% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Guangzhou Boji Medical and Biotechnological Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guangzhou Boji Medical and Biotechnological Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Guangzhou Boji Medical and Biotechnological Co Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Guangzhou Boji Medical and Biotechnological Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.40% | CN¥55.37 Million ≈ $8.10 Million |
CN¥1.63 Billion ≈ $238.44 Million |
+1.77pp |
| 2024-12-31 | 1.63% | CN¥23.68 Million ≈ $3.46 Million |
CN¥1.45 Billion ≈ $212.27 Million |
+1.12pp |
| 2023-12-31 | 0.52% | CN¥7.38 Million ≈ $1.08 Million |
CN¥1.43 Billion ≈ $209.10 Million |
-3.09pp |
| 2022-12-31 | 3.61% | CN¥45.69 Million ≈ $6.69 Million |
CN¥1.27 Billion ≈ $185.17 Million |
+1.85pp |
| 2021-12-31 | 1.76% | CN¥20.00 Million ≈ $2.93 Million |
CN¥1.14 Billion ≈ $166.56 Million |
-6.41pp |
| 2018-12-31 | 8.17% | CN¥49.50 Million ≈ $7.24 Million |
CN¥606.02 Million ≈ $88.68 Million |
+3.13pp |
| 2017-12-31 | 5.04% | CN¥28.96 Million ≈ $4.24 Million |
CN¥574.72 Million ≈ $84.10 Million |
-6.53pp |
| 2016-12-31 | 11.56% | CN¥60.00 Million ≈ $8.78 Million |
CN¥518.85 Million ≈ $75.92 Million |
-18.20pp |
| 2015-12-31 | 29.76% | CN¥154.80 Million ≈ $22.65 Million |
CN¥520.15 Million ≈ $76.11 Million |
-- |
About Guangzhou Boji Medical and Biotechnological Co Ltd
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. It offers pre-clinical research, clinical research, and other consulting services. The company also provides clinical drug production, pilot test scale-up, process verification batch … Read more